Summary & Overview
CPT 83051: Plasma Free Hemoglobin Measurement
CPT code 83051 represents a laboratory assay that measures free hemoglobin in plasma, used to detect hemolysis and assess intravascular red cell destruction. As a specialized clinical laboratory test, it informs diagnosis and management of hemolytic processes, transfusion reactions, and conditions that cause red blood cell breakdown. Nationally, accurate coding for this test supports appropriate clinical decision-making and ensures consistent billing for a discrete laboratory service.
Key payers discussed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The review outlines payer coverage considerations and common billing practices for this laboratory service.
Readers will learn what CPT code 83051 denotes clinically and operationally, where the service is typically performed, and which major payers are relevant for coverage discussions. The summary also previews benchmarks and policy-relevant topics typically examined for laboratory codes — including reimbursement patterns, coding compliance, and clinical context for test utilization. Data not available in the input is noted where applicable, and the material is presented for a national audience without state-specific references.
Billing Code Overview
CPT code 83051 measures free hemoglobin in plasma from an anticoagulated blood sample. The test quantifies the amount of hemoglobin present in the plasma (the liquid portion of blood) separate from intact red blood cells, detecting hemolysis or intravascular red cell destruction.
Service type: Clinical laboratory test — plasma free hemoglobin measurement
Typical site of service: Clinical laboratory or hospital laboratory
Clinical & Coding Specifications
Clinical Context
A typical patient is a 58-year-old adult presenting to an outpatient laboratory or hospital phlebotomy station after a clinician orders evaluation for hemolysis, transfusion reaction, or unexplained anemia. A venous blood sample is collected into an anticoagulated tube (eg, EDTA or heparin) and processed to separate plasma. The laboratory analyst performs a plasma hemoglobin measurement to detect free hemoglobin released from lysed red blood cells. Results support diagnosis and management of intravascular hemolysis, monitoring of patients after blood transfusion, evaluation of suspected mechanical hemolysis from prosthetic heart valves or extracorporeal circuits, and assessment of suspected severe burns or sepsis where hemolysis may occur.
Typical workflow: a clinician documents the indication and orders plasma free hemoglobin; phlebotomy labels and sends the anticoagulated specimen to the clinical chemistry lab; a medical technologist performs the assay (spectrophotometric or immunoassay-based), documents analytical notes, and releases results to the ordering provider; abnormal results prompt clinician correlation with hemoglobin, haptoglobin, lactate dehydrogenase, bilirubin, and direct antiglobulin testing as clinically indicated.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing only the interpretation/professional portion if the lab performs technical testing but a physician performs interpretation and bills separately. |